Status:
COMPLETED
Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
RATIONALE: Studying samples of tissue in the laboratory from patients who received cetuximab may help doctors understand and predict how well patients will respond to treatment. PURPOSE: This researc...
Detailed Description
OBJECTIVES: Primary * To determine, among patients with advanced CRC, whether the effect of treatment (cetuximab vs bevacizumab) on progression-free survival (PFS) depends on tumor BRAF V600E mutati...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Participation in CALGB-C80405
- Have KRAS WT or KRAS mut tumor
- Randomized to treatment with either bevacizumab or cetuximab alone
- Patients randomized to the combination therapy are not eligible
- Available specimens at the PCO for BRAF mutation detection
- Patient consent for use of samples
Exclusion
Key Trial Info
Start Date :
November 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2018
Estimated Enrollment :
1142 Patients enrolled
Trial Details
Trial ID
NCT01243372
Start Date
November 1 2009
End Date
January 1 2018
Last Update
July 24 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.